EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Seagen's Enterprise Value is $42,031 Mil.
Seagen's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-791 Mil. Therefore, Seagen's EV-to-EBIT for today is -53.17.
The historical rank and industry rank for Seagen's EV-to-EBIT or its related term are showing as below:
SGEN'
s EV-to-EBIT Range Over the Past 10 Years
Min: -51.59 Med: -47.73 Max: -34.43
Current: -50.35
During the past 13 years, the highest EV-to-EBIT of Seagen was -34.43. The lowest was -51.59. And the median was -47.73.
SGEN's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 8.05
vs SGEN: -50.35
The historical data trend for Seagen's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Seagen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seagen's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seagen's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Seagen's EV-to-EBIT falls into.
Seagen's current Enterprise Value is $42,031 Mil.
Seagen's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-791 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seagen (NAS:SGEN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Seagen's Enterprise Value for the quarter that ended in Sep. 2023 was $38,894 Mil.
Seagen's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-791 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seagen EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Seagen's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGEN has been successfully added to your 